Interestingly, tumors that recurred following IGF-IR downregulation in the mammary tumors acquired a claudin-low phenotype and genotype and expressed Cav-1 at significantly higher levels (~14-fold) than the initial mammary tumor [22]. This evidence concerns the gene IGF1R and breast cancer.